Oruka Therapeutics fixes purchase price error, adds employee warrants in merger with ARCA

Oruka Therapeutics, Inc.

July 3, 2024: Oruka and parties signed Letter Agreement correcting a scrivener's error in the Purchase Price definition.
Same day: Oruka entered an Amended and Restated Subscription Agreement adding warrants for certain employees and service providers.
Both actions relate to the pending merger with ARCA biopharma (ABIO) under the April 3, 2024 Merger Agreement.
No changes to the $275M aggregate subscription amount or other key deal terms; corrections are procedural.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.